

Bioimpedance as a tool for fluid management in peritoneal dialysis patients

Submission date 29/11/2008	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
Registration date 18/12/2009	Overall study status Completed	<input type="checkbox"/> Protocol
Last Edited 11/01/2017	Condition category Urological and Genital Diseases	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Prof Simon Davies

Contact details
Nephrology Department
University Hospital of North Staffordshire
Princes Road
Hartshill
Stoke on Trent
United Kingdom
ST4 7LN
-
simondavies1@compuserve.com

Additional identifiers

ClinicalTrials.gov (NCT)
NCT00801112

Study information

Scientific Title

Developing bioimpedance as a tool for fluid management in peritoneal dialysis patients: a validation study

Study objectives

Regular monitoring of bioimpedance (BIA) adds value to the management of fluid status in peritoneal dialysis (PD) patients.

Ethics approval required

Old ethics approval format

Ethics approval(s)

North Staffordshire Local Research Ethics Committee - submission pending as of 29/11/2008

Study design

Multi-centre randomised controlled trial

Primary study design

Interventional

Study type(s)

Other

Health condition(s) or problem(s) studied

End stage renal disease on peritoneal dialysis

Interventions

Clinician to use whatever tools at their disposal to achieve dry weight in PD patients including restricted dietary salt and fluid intake, increased use of hypertonic PD solutions and modality change. BIA to track fluid status changes. BIA measurements will also be taken for the control group but the results will not be acted upon

BIA measurements for all patients will be taken at 3 months intervals. The total duration of the intervention is 1 year.

Intervention Type

Other

Phase

Not Applicable

Primary outcome(s)

Extra-cellular fluid volume (ECFv) determined from BIA

Key secondary outcome(s)

Outcomes will be measured at 6-month intervals:

1. Blood pressure control (clinic)
2. Residual urine volume:
 - 2.1. Development of anuria (<200 ml/day)
 - 2.2. Time to halving of urine volume at randomisation
3. Membrane function:

- 3.1. Glucose exposure
- 3.2. Solute transport
- 3.3. Ultrafiltration (UF) capacity
- 3.4. Free water transport (limited centres, own resources)
- 4. Cardiac function:
 - 4.1. Brain natriuretic peptide (BNP) (all centres)
 - 4.2. Echocardiography (ECHO) (limited centres, own resources)
- 5. Fluid status using gold standard methods (limited centres, own resources)

Completion date

15/11/2011

Eligibility

Key inclusion criteria

- 1. All PD patients who are clinically stable
- 2. Age >16 years

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

All

Key exclusion criteria

- 1. Patients planning discontinuation of PD within 6 months
- 2. Patients who are unable to give consent
- 3. Patients who have peritonitis the last 30 days prior to study enrollment
- 4. Patients who are pregnant

Date of first enrolment

15/01/2009

Date of final enrolment

15/11/2011

Locations

Countries of recruitment

United Kingdom

England

Italy

Netherlands

Spain

Sweden

Study participating centre
University Hospital of North Staffordshire
Stoke on Trent
United Kingdom
ST4 7LN

Sponsor information

Organisation
University Hospital of North Staffordshire (UK)

Funder(s)

Funder type
Industry

Funder Name
Baxter (UK) - Clinical Evidence Council

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/02/2016		Yes	No